Skip to content

Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth

Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth

Nurturing Wellbeing in Our Workspace: Prioritizing People’s Growth

Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth

At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vibrant team. Today, let’s delve into how our Workplace Wellbeing initiatives align with our ESG principles, fostering a culture of growth and balance. These are more than just initiatives, but are our way to care about Scailyters:

Investing in people’s Growth: Our training and development programs aren’t just about skill enhancement. They represent our investment in our employees’ growth. From internal trainings that cater to domain expertise, to external courses that broaden horizons, we’re dedicated to empowering our team members.

Flexibility & Connection: Our work mode policy underscores our belief in flexibility. Whether people prefer the office environment or the comfort of home, we trust our Scailyters to make the choice that enhances personal productivity and overall wellbeing, as well as team productivity. And when we gather for team events or our annual retreat, it’s about more than just work – it’s about building connections and sparking creativity.

Healthy Habits, Happy Minds: Through our lunch subsidy program, we’re not just encouraging healthy eating, but also providing moments for our employees to unwind and connect over meals. After all, a healthy body nurtures a happy mind.

Recognition & Celebration: Achievements deserve recognition, and at Scailyte, we celebrate them! Our peer bonus and gift programs are designed to appreciate exceptional efforts and milestones. Because in a thriving ecosystem, every contribution matters.

The heart of our ESG mission lies in nurturing a workplace where growth is inherent, balance is celebrated, and every Scailyter thrives. Stay tuned as we continue this journey, evolving and innovating for our team members’ wellbeing.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Recent News

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Recent News

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Recent News

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

Recent News

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News

01 /04

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

02 /04

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

03 /04

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

04 /04

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News